Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
EMEA Revenue	692.77M	690.34M	667.83M
EMEA Revenue Growth	0.35%	3.37%	5.33%
APAC Revenue	101.03M	101.48M	96.24M
APAC Revenue Growth	-0.45%	5.45%	-6.48%
North America Revenue	321.83M	362.06M	308.95M
North America Revenue Growth	-11.11%	17.19%	-2.71%
South America Revenue	29.47M	32.40M	31.02M
South America Revenue Growth	-9.04%	4.44%	0.49%
Revenue (Other)	-536.63M	-	1,000.00
Revenue (Total)	608.47M	1.19B	1.10B
Revenue (Total) Growth	-48.71%	7.45%	1.72%

Revenue

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Revenue	976.82M	1.04B	933.74M
Biopharmaceutical and Diagnostic Solutions Revenue Growth	-5.91%	11.18%	6.19%
Engineering Revenue	168.28M	148.11M	170.29M
Engineering Revenue Growth	13.62%	-13.03%	-17.36%
Revenue (Other)	-536.63M	-	-
Revenue (Total)	608.47M	1.19B	1.10B
Revenue (Total) Growth	-48.71%	7.45%	1.72%

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Gross Profit	298.47M	328.15M	268.78M
Biopharmaceutical and Diagnostic Solutions Gross Profit Growth	-9.04%	22.09%	-7.39%
Engineering Gross Profit	47.14M	31.02M	56.17M
Engineering Gross Profit Growth	51.98%	-44.78%	-28.22%
Eliminations from Gross Profit	-24.54M	-15.29M	-22.63M
Gross Profit (Other)	-148.43M	-	-
Gross Profit (Total)	172.64M	343.88M	302.32M
Gross Profit (Total) Growth	-49.80%	13.75%	-11.05%

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Operating Profit	193.51M	220.43M	165.64M
Biopharmaceutical and Diagnostic Solutions Operating Profit Growth	-12.21%	33.08%	-11.70%
Engineering Operating Profit	28.95M	9.33M	33.10M
Engineering Operating Profit Growth	210.32%	-71.81%	-38.27%
Eliminations from Operating Profit	-38.58M	-30.95M	-37.59M
Operating Income (Other)	-76.05M	-	-
Operating Income (Total)	107.83M	198.80M	161.14M
Operating Income (Total) Growth	-45.76%	23.37%	-19.72%

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Backlog	871.00M	853.00M
Backlog Growth	2.11%	-9.73%

Updated Mar 4, 2026. Data Source: Fiscal.ai.